Structured Treatment Interruptions Workshop Summary
January 31, 2001
The aggregate of experience from many small studies, anecdotal reports and observational databases provides what we know so far about the safety of STI. Despite this experience, reproducible HIV-1-specific immune control has not yet been demonstrated.
The number of variables that must be considered when designing trials to evaluate potential immune benefits are daunting: The duration of a scheduled interruption may be determined by:
(CD4+ or RNA triggers can be defined as absolute numbers or as relative changes from a setpoint.)
The choice of number and duration of subsequent interruptions multiplies the variables:
The duration of treatment after interruption is another consideration:
Hypotheses exist to support each of these approaches, and evidence from animal models can be used to argue for one or another. Short of hitting on a lucky combination in another round of small trials, much basic science and animal research may be needed before interruption schedules for large Phase III trials can be confidently selected. Appendix 2
This article was provided by Project Inform. Visit Project Inform's website to find out more about their activities, publications and services.